Navigation Links
VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo for Cancer Research and Diagnostics
Date:6/24/2008

ST. JOSEPH, Mich., June 24 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that VTT has licensed MetaCore(TM). VTT develops novel high-throughput methods for cancer research, drug discovery and diagnostics. The focus is in investigating mechanisms of cancer development and progression, identification of therapeutic targets and exploration of the mechanism of action of anti-cancer compounds. VTT will utilize MetaCore and MetaDrug in high-throughput compound screening, RNA interference experiments, cell biology and bioinformatics projects to identify pathways and networks important in translational cancer research.

There are 85 researchers and staff members working in VTT's Medical Biotechnology Knowledge Centre in Turku. The research is funded by the European Commission and the Academy of Finland. VTT accommodates two EU Marie Curie Centre of Excellence teams and coordinates the Academy of Finland Centre of Excellence for translational genome-wide biology. Further information on VTT: http://www.vtt.fi.

"VTT was our first customer in Finland and an important internationally recognized cancer research center," said Julie Bryant, GeneGo's VP of Business development. "We have seen a growing need for analysis platforms focused in disease areas recently. We responded by developing disease pathway ontologies, biomarker and drug databases and new interactome analysis tools. We are pleased that our expertise in cancer is appreciated by professional molecular oncologists at VTT."

About GeneGo, Inc.

GeneGo, Inc. systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.7(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.7(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com

MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nikon Instruments Begins Direct Sales and Technical Support in Southern California and Rocky Mountain Territories
2. Mr. Richard Decker Appointed Technical Director of Edgewood Chemical Biological Center
3. Genencor Appoints New Executive Vice President - Technical Enzymes
4. Biomaxx Systems Inc. Selected as Technical Consultant By Southern Cross Agricultural Developments
5. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
6. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
7. Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.
8. Decision Resources, Inc. Acquires Manhattan Research
9. Partnering for Philanthropy Conference Launched to Unite Innovative Non-profit Research Organizations with Philanthropists and Industry
10. HIPAA Privacy Rule Impedes Biomedical Research
11. Stem Cell Researcher Wins Award for Excellence for Work With the ImageStream(R) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
Breaking Biology Technology:
(Date:6/21/2016)... , June 21, 2016 NuData Security announced ... new role of principal product architect and that ... director of customer development. Both will report directly ... officer. The moves reflect NuData,s strategic growth in ... to high customer demand and customer focus values. ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):